{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:04:18Z","timestamp":1789193058853,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.eururo.2006.01.017","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T09:54:49Z","timestamp":1138355689000},"page":"790-797","source":"Crossref","is-referenced-by-count":157,"title":["Management of BCG Failures in Superficial Bladder Cancer: A Review"],"prefix":"10.1016","volume":"49","author":[{"given":"Johannes A.","family":"Witjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.01.017_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2005.05.011","article-title":"EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ","volume":"48","author":"van der Meijden","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours","volume":"41","author":"Patard","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance nacillus Calmette-Guerin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer?","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","article-title":"Bacille Calmette-Guerin in superficial transitional cell carcinoma","volume":"82","author":"Mungan","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.01.017_bib11","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumours","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0302-2838(02)00491-8","article-title":"Beware the BCG failures: a review of one institution\u2019s results","volume":"42","author":"Lockyer","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1464-410x.1999.00208.x","article-title":"Elevated urinary fibronectin levels after transurethral resection of bladder tumour: a possible role in patients failing therapy with bacillus Calmette-Guerin","volume":"84","author":"Laufer","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.01.017_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2006.01.017_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2006.01.017_bib21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2003.11.018","article-title":"Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG)","volume":"45","author":"Saint","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumours: possible implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000052521","article-title":"The use of valrubicin for the chemoresection of superficial bladder cancer\u2014a marker lesion study","volume":"39","author":"Newling","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib29","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.01.017_bib30","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.01.017_bib31","unstructured":"van der Heijden AG, Moonen PMJ, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of Eoquin\u2122 in superficial bladder cancer\u2014toxicity and marker response. Submitted."},{"key":"10.1016\/j.eururo.2006.01.017_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","article-title":"Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin","volume":"5","author":"Sarosdy","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.01.017_bib33","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"issue":"suppl","key":"10.1016\/j.eururo.2006.01.017_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-5347(18)35074-2","article-title":"Factors affecting response to BCG plus interferon \u03b1 patients with urothelial CIS","volume":"173","author":"Maymi","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000052419","article-title":"Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion","volume":"39","author":"Colombo","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.01.017_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"Van Der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib39","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","article-title":"Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","article-title":"Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study","volume":"61","author":"Berger","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.01.017_bib41","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2005.11.010","article-title":"Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.01.017_bib43","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/bjc.1993.147","article-title":"The clinical epidemiology of superficial bladder cancer","volume":"67","author":"Kiemeney","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2006.01.017_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","article-title":"A second-look TUR in T1 transitional cell carcinoma: why?","volume":"45","author":"Jakse","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib45","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.1998.16.3.1099","article-title":"Extravesical tumour relapse in patients with superficial bladder tumours","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.01.017_bib46","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0022-5347(05)64157-2","article-title":"Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience","volume":"168","author":"Vallancien","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.01.017_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ucl.2005.02.001","article-title":"Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction","volume":"32","author":"Hautmann","year":"2005","journal-title":"Urol Clin North Am"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T12:22:25Z","timestamp":1555417345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0302283806000352"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.01.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}